CTAD 2026 — Clinical Trials on Alzheimer's Disease
Dates: November 16-19, 2026
Location: Boston, Massachusetts, USA
Organizer: CTAD (Clinical Trials on Alzheimer's Disease)
Website: [ctad-alzheimer.com](https://ctad-alzheimer.com)
Overview
Mermaid diagram (expand to render)
CTAD 2026 will be the 19th annual Clinical Trials on Alzheimer's Disease conference, held in Boston, Massachusetts. This premier event continues its tradition of presenting the most important clinical trial results in Alzheimer's disease, bringing together researchers, pharmaceutical companies, and regulatory agencies to advance treatments["@ctad"].
CTAD has become the defining venue for late-breaking clinical trial data in Alzheimer's disease and dementia. The conference uniquely bridges academic research, pharmaceutical development, and regulatory science, making it essential for anyone involved in Alzheimer's therapeutic development["@ctad2025"].
Conference Highlights
Key Dates
April 2026: Registration opens
June 2026: Abstract submission deadline
September 2026: Late-breaking abstract submission
November 16-19, 2026: Main conference
Expected Highlights
Late-breaking clinical trial results
Regulatory guidance sessions
Biomarker validation studies
Prevention trial updates
Session Types
Late-Breaking Trials: Results from recently completed Phase 2/3 trials
Platform Presentations: Selected abstracts on therapeutic interventions
Poster Sessions: Ongoing research and subgroup analyses
Regulatory Sessions: FDA, EMA, and PMDA guidance
Workshops: Clinical trial methodology and design
Conference Focus
Clinical Trial Results
CTAD is renowned for presenting late-breaking clinical trial data:
Disease-Modifying Therapies
[Lecanemab](/therapeutics/lecanemab) ([Leqembi](/therapeutics/lecanemab)) — Anti-amyloid antibody with Phase 3 CLARITY-AD data[@van2023]
[Donanemab](/therapeutics/donanemab) ([Kisunla](/therapeutics/donanemab)) — Anti-amyloid antibody with TRAILBLAZER-ALZ 2 results[@sims2023]
Next-generation anti-amyloid antibodies — Novel candidates in development
Anti-[tau](/proteins/tau) immunotherapies — Multiple programs in Phase 2/3[@mullard2024]
Synaptic protection — Novel mechanisms targeting synaptic function
Combination approaches — Multi-target strategies for enhanced efficacy
Symptomatic Treatments
Cognitive enhancers
Neuropsychiatric symptom management
Sleep and circadian interventions
Prevention Trials
A4 Study: Anti-amyloid treatment in preclinical Alzheimer's
CTAD 2026 will feature critical updates on disease-modifying therapies for Alzheimer's disease, representing the next generation of treatments beyond amyloid-targeting antibodies.
Amyloid-Targeting Therapies
Lecanemab (Leqembi) Updates
The [Lecanemab](/therapeutics/lecanemab) program will present:
Clarity-OLE Data: Long-term safety and efficacy from the open-label extension study, demonstrating sustained cognitive benefits with continued treatment
Real-World Effectiveness: Post-marketing data on real-world patient outcomes
ARIA Management: Updated protocols for amyloid-related imaging abnormality monitoring and management
Combination Approaches: Early data on potential combination with tau-targeting agents
Donanemab (Kisunla) Updates
[Donanemab](/therapeutics/donanemab) will present:
TRAILBLAZER-ALZ 3: Prevention trial in preclinical Alzheimer's
Biomarker Correlation: p-tau217 and other fluid biomarker changes as treatment response indicators
Tau PET Subgroup Analysis: Impact of baseline tau pathology on treatment response
Patient Selection: Refined enrichment strategies based on biomarker profiles
Next-Generation Anti-Amyloid Antibodies
Pipeline programs expected to present:
Gantenerumab (Roche): GRADUATE program results
Crenezumab (Roche): CREAD program data and re-analysis
Novel candidates: Early-phase data on next-generation antibodies with improved brain penetration
Tau-Targeting Therapies
The tau therapy field has accelerated significantly, with multiple programs in late-stage development:
Anti-Tau Antibodies
[E2814](/therapeutics/e2814-tau-antibody) (Eisai): First-generation anti-tau antibody in Phase 3
[CTAD Past Conferences](https://ctad-alzheimer.com/past-conferences)
[Alzheimer's Association Clinical Trials](https://www.alz.org/trialmatch)
References
Unknown, CTAD Conference Series (n.d.)
Unknown, CTAD 2025 Conference Review (2025)
[van Dyck CH, et al., Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 (2023)](https://doi.org/10.1056/NEJMoa2212948)
[Sims JR, et al., Donanemab in Early Symptomatic Alzheimer Disease. JAMA. 2023 (2023)](https://doi.org/10.1001/jama.2023.13239)
[Unknown, Mullard A. Tau-targeting therapies advance in Alzheimer's disease. Nat Rev Drug Discov. 2024 (2024)](https://doi.org/10.1038/d41573-024-00114-3)
Unknown, FDA Alzheimer's Disease Drug Development Guidance (n.d.)
[Cummings J, et al., Alzheimer's disease drug development pipeline 2024. Alzheimer's Dement. 2024 (2024)](https://doi.org/10.1002/alz.13809)
[Aisen PS, et al., Tau targeting therapies in Alzheimer's disease. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00867-9)